Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Autosomal recessive hypercholesterolemia in a kindred of Syrian ancestry

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Genetic variants in SUSD2 are associated with the risk of ischemic heart disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. GPIHBP1 autoantibody syndrome during interferon β1a treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. An enzyme-linked immunosorbent assay for measuring GPIHBP1 levels in human plasma or serum

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The intrinsic instability of the hydrolase domain of lipoprotein lipase facilitates its inactivation by ANGPTL4-catalyzed unfolding

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Small-Molecule Inhibition of the uPAR ⋅ uPA Interaction by Conformational Selection

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Chylomicronemia From GPIHBP1 Autoantibodies Successfully Treated With Rituximab: A Case Report

    Research output: Contribution to journalLetterpeer-review

  5. Chylomicronemia from GPIHBP1 autoantibodies

    Research output: Contribution to journalReviewpeer-review

  • Ambika P Ashraf
  • Kazuya Miyashita
  • Katsuyuki Nakajima
  • Masami Murakami
  • Robert A Hegele
  • Michael Ploug
  • Loren G Fong
  • Stephen G Young
  • Anne P Beigneux
View graph of relations

Chylomicronemia caused by a deficiency in lipoprotein lipase (LPL) or GPIHBP1 (the endothelial cell protein that transports LPL to the capillary lumen) is typically diagnosed during childhood and represents a serious, lifelong medical problem. Affected patients have high plasma triglyceride levels (>1500 mg/dL) and a high risk of acute pancreatitis. However, chylomicronemia frequently presents later in life in the absence of an obvious monogenic cause. In these cases, the etiology for the chylomicronemia is presumed to be "multifactorial" (involving diabetes, drugs, alcohol, or polygenic factors), but on a practical level, the underlying cause generally remains a mystery. Here, we describe a 15-year-old female with chylomicronemia caused by GPIHBP1 autoantibodies (which abolish LPL transport to the capillary lumen). Remarkably, chylomicronemia in this patient was intermittent, interspersed between periods when the plasma triglyceride levels were normal. GPIHBP1 autoantibodies were easily detectable during episodes of chylomicronemia but were undetectable during periods of normotriglyceridemia. During the episodes of chylomicronemia (when GPIHBP1 autoantibodies were present), plasma LPL levels were low, consistent with impaired LPL transport into capillaries. During periods of normotriglyceridemia, when GPIHBP1 autoantibodies were absent, plasma LPL levels normalized. Because the chylomicronemia in this patient was accompanied by debilitating episodes of acute pancreatitis, the patient was ultimately treated with immunosuppressive drugs, which resulted in disappearance of GPIHBP1 autoantibodies and normalization of plasma triglyceride levels. GPIHBP1 autoantibodies need to be considered in patients who present with unexplained acquired cases of chylomicronemia.

Original languageEnglish
JournalJournal of Clinical Lipidology
Volume14
Issue number2
Pages (from-to)197-200
Number of pages4
ISSN1933-2874
DOIs
Publication statusPublished - 29 Feb 2020

    Research areas

  • GPIHBP1, lipoprotein lipase, LPL

ID: 59783166